Barclays’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-21,498
| Closed | -$39.8K | – | 5315 |
|
|
2023
Q1 | $39.8K | Sell |
21,498
-16,573
| -44% | -$20.5K | ﹤0.01% | 4502 |
|
|
2022
Q4 | $42.3K | Buy |
38,071
+9,528
| +33% | +$13.6K | ﹤0.01% | 4607 |
|
|
2022
Q3 | $66K | Sell |
28,543
-241,743
| -89% | -$856K | ﹤0.01% | 3695 |
|
|
2022
Q2 | $819K | Sell |
270,286
-189,623
| -41% | -$922K | ﹤0.01% | 2513 |
|
|
2022
Q1 | $3.12M | Sell |
459,909
-258,710
| -36% | -$1.84M | ﹤0.01% | 1530 |
|
|
2021
Q4 | $6M | Buy |
718,619
+678,473
| +1,690% | +$5.59M | ﹤0.01% | 1571 |
|
|
2021
Q3 | $298K | Sell |
40,146
-2,392
| -6% | -$14.8K | ﹤0.01% | 3425 |
|
|
2021
Q2 | $290K | Buy |
42,538
+19,196
| +82% | +$159K | ﹤0.01% | 3372 |
|
|
2021
Q1 | $239K | Buy |
23,342
+17,773
| +319% | +$195K | ﹤0.01% | 3627 |
|
|
2020
Q4 | $39K | Sell |
5,569
-2,833
| -34% | -$22K | ﹤0.01% | 4519 |
|
|
2020
Q3 | $68K | Sell |
8,402
-1,134
| -12% | -$7.03K | ﹤0.01% | 4451 |
|
|
2020
Q2 | $66K | Buy |
9,536
+3,945
| +71% | +$21.3K | ﹤0.01% | 4786 |
|
|
2020
Q1 | $26K | Sell |
5,591
-10,924
| -66% | -$62.9K | ﹤0.01% | 5560 |
|
|
2019
Q4 | $144K | Buy |
16,515
+5,578
| +51% | +$30.1K | ﹤0.01% | 5266 |
|
|
2019
Q3 | $37K | Sell |
10,937
-2,559
| -19% | -$10.2K | ﹤0.01% | 6032 |
|
|
2019
Q2 | $67K | Sell |
13,496
-16,874
| -56% | -$89.6K | ﹤0.01% | 5948 |
|
|
2019
Q1 | $189K | Sell |
30,370
-8,564
| -22% | -$41.4K | ﹤0.01% | 4868 |
|
|
2018
Q4 | $131K | Sell |
38,934
-25,100
| -39% | -$117K | ﹤0.01% | 4870 |
|
|
2018
Q3 | $415K | Buy |
64,034
+13,546
| +27% | +$101K | ﹤0.01% | 4428 |
|
|
2018
Q2 | $387K | Sell |
50,488
-23,295
| -32% | -$336K | ﹤0.01% | 4174 |
|
|
2018
Q1 | $1.65M | Buy |
73,783
+68,888
| +1,407% | +$1.53M | ﹤0.01% | 2677 |
|
|
2017
Q4 | $62K | Buy |
4,895
+197
| +4% | +$2.9K | ﹤0.01% | 5622 |
|
|
2017
Q3 | $74K | Buy |
4,698
+2,093
| +80% | +$29.6K | ﹤0.01% | 5138 |
|
|
2017
Q2 | $36K | Buy |
2,605
+1,205
| +86% | +$25.8K | ﹤0.01% | 5524 |
|
|
2017
Q1 | $31K | Buy |
+1,400
| New | +$29.7K | ﹤0.01% | 5600 |
|
Other funds holding JNCE
Barclays's JNCE Position: Q2 2023 in Review
Barclays sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 21,498 shares — an estimated $39.8K sold.
Barclays first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $6M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Barclays reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Barclays sold 21,498 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $39.8K.
- Barclays first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Barclays's Jounce Therapeutics, Inc. Common Stock position peaked at $6M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.